RUNX1 Gene Platelet Disorder with Associated Myeloid Malignancy Genetic Test
Test Name: RUNX1 Gene Platelet disorder with associated myeloid malignancy Genetic Test
Components: Blood or Extracted DNA or One drop Blood on FTA Card
Price: 4400.0 AED
Report Delivery: 3 to 4 Weeks
Method: NGS Technology
Test Type: Hematology
Doctor: Hematologist
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for RUNX1 Gene Platelet disorder with associated myeloid malignancy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with RUNX1 Gene Platelet disorder with associated myeloid malignancy NGS Genetic DNA Test gene RUNX1
Test Details
The RUNX1 gene is a transcription factor that plays a crucial role in the development and maturation of blood cells. Mutations or abnormalities in the RUNX1 gene can lead to a rare genetic disorder known as “RUNX1 gene platelet disorder with associated myeloid malignancy” (also known as “Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia” or “FPD/AML”).
This disorder is characterized by a predisposition to develop abnormal bleeding tendencies due to a decrease in the number and function of platelets. Platelets are responsible for blood clotting, and a decrease in their number or function can lead to easy bruising, nosebleeds, and excessive bleeding.
In addition to the platelet disorder, individuals with FPD/AML have an increased risk of developing myeloid malignancies, particularly acute myeloid leukemia (AML). AML is a type of cancer that affects the bone marrow and leads to the overproduction of immature white blood cells.
NGS (Next-Generation Sequencing) genetic testing is a powerful tool used to analyze the DNA sequence of the RUNX1 gene and identify any mutations or abnormalities. This type of testing can help diagnose FPD/AML and determine the risk of developing myeloid malignancies.
NGS genetic testing involves extracting DNA from a patient’s blood sample and using specialized techniques to sequence the entire RUNX1 gene. The DNA sequence data is then analyzed, and any mutations or abnormalities in the gene are identified.
This information can help healthcare professionals provide appropriate management and surveillance for individuals with FPD/AML, including regular blood tests and monitoring for the development of myeloid malignancies.
It is important to note that NGS genetic testing for FPD/AML is typically recommended for individuals with a family history of the disorder or those who present with unexplained bleeding tendencies or myeloid malignancies at a young age. Genetic counseling is often recommended before and after testing to discuss the implications of the results and provide support to individuals and their families.
| Test Name | RUNX1 Gene Platelet disorder with associated myeloid malignancy Genetic Test |
|---|---|
| Components | |
| Price | 4400.0 AED |
| Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
| Report Delivery | 3 to 4 Weeks |
| Method | NGS Technology |
| Test type | Hematology |
| Doctor | Hematologist |
| Test Department: | Genetics |
| Pre Test Information | Clinical History of Patient who is going for RUNX1 Gene Platelet disorder with associated myeloid malignancy NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with RUNX1 Gene Platelet disorder with associated myeloid malignancy NGS Genetic DNA Test gene RUNX1 |
| Test Details | The RUNX1 gene is a transcription factor that plays a crucial role in the development and maturation of blood cells. Mutations or abnormalities in the RUNX1 gene can lead to a rare genetic disorder known as “RUNX1 gene platelet disorder with associated myeloid malignancy” (also known as “Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia” or “FPD/AML”). This disorder is characterized by a predisposition to develop abnormal bleeding tendencies due to a decrease in the number and function of platelets. Platelets are responsible for blood clotting, and a decrease in their number or function can lead to easy bruising, nosebleeds, and excessive bleeding. In addition to the platelet disorder, individuals with FPD/AML have an increased risk of developing myeloid malignancies, particularly acute myeloid leukemia (AML). AML is a type of cancer that affects the bone marrow and leads to the overproduction of immature white blood cells. NGS (Next-Generation Sequencing) genetic testing is a powerful tool used to analyze the DNA sequence of the RUNX1 gene and identify any mutations or abnormalities. This type of testing can help diagnose FPD/AML and determine the risk of developing myeloid malignancies. NGS genetic testing involves extracting DNA from a patient’s blood sample and using specialized techniques to sequence the entire RUNX1 gene. The DNA sequence data is then analyzed, and any mutations or abnormalities in the gene are identified. This information can help healthcare professionals provide appropriate management and surveillance for individuals with FPD/AML, including regular blood tests and monitoring for the development of myeloid malignancies. It is important to note that NGS genetic testing for FPD/AML is typically recommended for individuals with a family history of the disorder or those who present with unexplained bleeding tendencies or myeloid malignancies at a young age. Genetic counseling is often recommended before and after testing to discuss the implications of the results and provide support to individuals and their families. |
